Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lorcaserin - Eisai Inc

Next Previous
X
Search
Drug Profile

Lorcaserin - Eisai Inc

Alternative Names: APD-356; Belviq; Belviq XR; E2023; Lorcaserin controlled-release; Lorcaserin extended-release; Lorcaserin hydrochloride; Venespri

Latest Information Update: 28 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arena Pharmaceuticals
  • Developer Arena Pharmaceuticals; CY Biotech; Eisai Inc; Ildong Pharmaceutical
  • Class Antiepileptic drugs; Benzazepines; Obesity therapies; Small molecules
  • Mechanism of Action 5-HT2C serotonin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dravet syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Obesity
  • Phase III Dravet syndrome
  • No development reported Epilepsy
  • Discontinued Smoking withdrawal

Most Recent Events

  • 28 Nov 2024 No recent reports of development identified for clinical-Phase-Unknown development in Dravet-syndrome in Unknown (PO, Tablet)
  • 28 Nov 2024 No recent reports of development identified for clinical-Phase-Unknown development in Epilepsy(Treatment-experienced) in Unknown (PO, Tablet)
  • 15 Aug 2024 Eisai terminated phase-III MOMENTUM 1 trials in Dravet syndrome (In children) in Canada, USA (PO) due to sponsor and the decision (NCT04572243)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top